Effect of azithromycin on murine arteriosclerosis exacerbated by Chlamydia pneumomiae

Journal of Infectious Diseases

Volumn 183, Issue 2, 2001, Pages 232-238

  Rothstein, Neil M ^a   Quinn, Thomas C ^b,c   Madico, Guillermo ^b   Gaydos, Charlotte A ^b   Lowenstein, Charles J ^a  

^a Cardiology Division   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; AZITHROMYCIN; PLACEBO;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMICROBIAL ACTIVITY; AORTA DISEASE; ARTERIOSCLEROSIS; ARTICLE; ATHEROGENESIS; BACTERIAL PNEUMONIA; CHLAMYDOPHILA PNEUMONIAE; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; DOSE RESPONSE; INFLAMMATION; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIBODIES, BACTERIAL; AORTA; APOLIPOPROTEINS E; ARTERIOSCLEROSIS; AZITHROMYCIN; CHLAMYDOPHILA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; FEMALE; LIPIDS; MICE; MICE, INBRED C57BL; POLYMERASE CHAIN REACTION;

EID: 0035863584     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/317941     Document Type: Article

References (72)

1. Atherosclerosis: Basic mechanisms: Oxidation, inflammation, and genetics
2. Atherosclerosis: An inflammatory disease
3. Atherosclerosis, inflammation, and infection
4. Role of infections in atherosclerosis
5. Infection and atherosclerosis: Emerging mechanistic paradigms
6. Infection and atherosclerosis: Focus on cytomegalovirus and Chlamydia pneumoniae
7. Pathogenesis of atherosclerosis: A possible relation to infection
8. Bacterial infections and atherosclerosis
9. Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease
10. Role of infection as a risk factor for atherosclerosis, myocardial infarction, and stroke
11. Infection as a risk factor for infarction and atherosclerosis
12. Mouse models of Chlamydia pneumoniae infection and atherosclerosis
13. Interaction of Chlamydia pneumoniae infection with other risk factors of atherosclerosis
14. Infection with Chlamydia pneumoniae and atherosclerosis: A review
15. Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure?
16. Chronic infection in the aetiology of atherosclerosis: Focus on Chlamydia pneumoniae
17. Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis?
18. Infection with Chlamydia pneumoniae accelerates the development of atherosclerosis and treatment with azithromycin prevents it in a rabbit model
19. Chronic infection in the etiology of atherosclerosis: The case for Chlamydia pneumoniae
20. Murine models of Chlamydia pneumoniae infection and atherosclerosis
21. Serological evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction
22. Chronic Chlamydia pneumoniae infection as a risk factor for coronary heart disease in the Helsinki Heart Study
23. Association of Chlamydia pneumoniae and acute coronary heart disease events in non-insulin dependent diabetic and non-diabetic subjects in Finland
24. Chlamydia pneumoniae is a risk factor for coronary heart disease in symptom-free elderly men, but Helicobacter pylori and cytomegalovirus are not
25. Association of Helicobacter pylori and Chlamydia pneumoniae infections with coronary heart disease and cardiovascular risk factors
26. Past infection by Chlamydia pneumoniae strain TWAR and asymptomatic carotid atherosclerosis
27. Association of prior infection with Chlamydia pneumoniae and angiographically demonstrated coronary artery disease
28. Lp(a) lipoprotein, IgG, IgA and IgM antibodies to Chlamydia pneumoniae and HLA class II genotype in early coronary artery disease
29. Circulating immune complexes containing chlamydial lipopolysaccharide in acute myocardial infarction
30. Chlamydia pneumoniae-specific circulating immune complexes in patients with chronic coronary heart disease
31. Chlamydia pneumoniae strain TWAR antibody and angiographically demonstrated coronary artery disease
32. Chlamydia pneumoniae and acute myocardial infarction in Jerusalem
33. Failure to detect Chlamydia pneumoniae in coronary atheromas of patients undergoing atherectomy
34. Lack of association between prior infection with Chlamydia pneumoniae and acute or chronic coronary artery disease
35. Lack of association between seropositivity to Chlamydia pneumoniae and carotid atherosclerosis
36. Prospective study of Chlamydia pneumoniae IgG seropositivity and risks of future myocardial infarction
37. Detection of Chlamydia pneumoniae in atherosclerotic plaques in the walls of arteries of lower extremities from patients undergoing bypass operation for arterial obstruction
38. Detection of Chlamydia pneumoniae in aortic lesions of atherosclerosis by immunocytochemical stain
39. Demonstration of Chlamydia pneumoniae in atherosclerotic lesions of coronary arteries
40. Chlamydia pneumoniae (TWAR) in coronary arteries of young adults (15-34 years old)
41. Detection of Chlamydia pneumoniae TWAR in human coronary atherectomy tissues
42. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis
43. Increased incidence of Chlamydia species within the coronary arteries of patients with symptomatic atherosclerotic versus other forms of cardiovascular disease
44. Chlamydia pneumoniae (TWAR) in atherosclerosis of the carotid artery
45. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen
46. Chlamydia pneumoniae, cytomegalovirus, and herpes simplex virus in atheroselerosis of the carotid artery
47. Detection of Chlamydia pneumoniae but not Helicobacter pylori in atherosclerotic plaques of aortic aneurysms
48. Detection and widespread distribution of Chlamydia pneumoniae in the vascular system and its possible implications
49. Low prevalence of Chlamydia pneumoniae in atherectomy specimens from patients with coronary heart disease
50. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction
51. Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection. Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study
52. Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes: The final report of the ROXIS Study
53. WIZARD and the design of trials for secondary prevention of atherosclerosis with antibiotics
54. Description and status of the azithromycin and coronary events study (ACES)
55. Rabbit model for Chlamydia pneumoniae infection
56. Chlamydia pneumoniae infection induces inflammatory changes in the aortas of rabbits
57. De novo induction of atherosclerosis by Chlamydia pneumoniae in a rabbit model
58. Chlamydia pneumoniae infection accelerates the progression of atherosclerosis in apolipoprotein E-deficient mice
59. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae
60. Chronic infections and coronary heart disease: Is there a link?
61. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells
62. Formalinized Chlamydia trachomatis organisms as antigen in the micro-immunofluorescence test
63. Touchdown enzyme time release-PCR for detection and identification of Chlamydia trachomatis, C. pneumoniae, and C. psittaci using the 16S and 16S-23S spacer rRNA genes
64. Variation in susceptibility to atherosclerosis among inbred strains of mice
65. Anti-inflammatory activity of macrolide antibiotics
66. Comparative anti-inflammatory effects of roxithromycin, azithromycin and clarithromycin
67. Membrane-stabilizing, anti-inflammatory interactions of macrolides with human neutrophils
68. Effects of two antibiotic regimens on course and persistence of experimental Chlamydia pneumoniae TWAR pneumonitis
69. Reactivation of Chlamydia pneumoniae infection in mice by cortisone treatment
70. Reactivation of Chlamydia pneumoniae lung infection in mice by cortisone
71. Reactivation of Chlamydia trachomatis lung infection in mice by cortisone
72. The anti-inflammatory effects of macrolides